M. Al-Alawi (Dublin 5, Ireland), M. van den Berge (Groningen, Netherlands), T. Maes (Ghent, Belgium), M. Schmidt (Groningen, Netherlands)
Reproducibility of COPD blood eosinophil counts T. Southworth (Manchester, United Kingdom), G. Beech (Manchester, United Kingdom), U. Kolsum (Manchester, United Kingdom), D. Singh (Manchester, United Kingdom)
|  |
Blood eosinophils in COPD: relationship with CLCA1 and mucus production G. Long (Manchester, United Kingdom), U. Kolsum (Manchester, United Kingdom), A. Higham (Manchester, United Kingdom), S. Sridhar (Gaithersburg, MD, United States of America), T. Pham (Gaithersburg, MD, United States of America), T. Southworth (Manchester, United Kingdom), P. Newbold (Gaithersburg, MD, United States of America), D. Singh (Manchester, United Kingdom)
|   |
Oropharyngeal and sputum microbiome dynamics with the same pattern following exacerbation of chronic obstructive pulmonary disease J. Su (Guangzhou, China), H. Liu (Guangzhou, China), Y. Lin (Guangzhou, China), H. Zhou (Guangzhou, China)
|   |
The impact of smoking on airway microbiome and mycobiome of COPD/AECOPD patients J. Su (Guangzhou, China), H. Liu (Guangzhou, China), Y. Lin (Guangzhou, China), R. Chen (Guangzhou, China)
|   |
The study of airway microbiome and mycobiome of COPD and AECOPD patients J. Su (Guangzhou, China), H. Liu (Guangzhou, China), Y. Lin (Guangzhou, China), R. Chen (Guangzhou, China)
|   |
Association of ER22/23EK glucocorticoid receptor gene polymorphism with glucocorticoids dosage in COPD V. Djordjevic (Nis, Republic of Serbia), M. Despotovic (Nis, Republic of Serbia), I. Stankovic (Nis, Republic of Serbia), T. Jevtovic Stoimenov (Nis, Republic of Serbia)
|  |
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s) W. Chen (Oxford, United Kingdom), C. Hardman (Oxford, United Kingdom), P. Batty (Oxford, United Kingdom), J. Luo (Oxford, United Kingdom), Y. Wu (Oxford, United Kingdom), L. Xue (Oxford, United Kingdom), G. Ogg (Oxford, United Kingdom), D. Sandham (Cambridge MA, United States of America), V. Erpenbeck (Basel, Switzerland)
|   |
Cholinergic muscarinic receptors and airway remodelling in severe asthma F. Ricciardolo (Turin, Italy), A. Folino (Turin, Italy), V. Carriero (Turin, Italy), M. Bullone (Turin, Italy), M. Pieper ( Ingelheim am Rhein, Germany)
|  |
Longitudinal measurement of VOCs in breath demonstrates pharmacokinetic washout curve J. Boschmans (Cambridge, United Kingdom), R. Smith (Cambridge, United Kingdom), R. Parris (Cambridge, United Kingdom), B. Boyle (Cambridge, United Kingdom), D. Apthorp (Cambridge, United Kingdom), S. Kitchen (Cambridge, United Kingdom), M. van der Schee (Amsterdam, Netherlands)
|  |
Investigating the safety of capsaicin cough challenge in severe asthma R. Wang (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom), R. Niven (Manchester, United Kingdom), D. Ryan (Manchester, United Kingdom), K. Holt (Manchester, United Kingdom), J. Mitchell (Manchester, United Kingdom), R. Dockry (Manchester, United Kingdom), B. Al-Sheklly (Manchester, United Kingdom), I. Satia (Manchester, United Kingdom), J. Smith (Manchester, United Kingdom)
|   |
Inhaled LPS challenge in healthy subjects: a dose escalation study A. Mulvanny (Manchester, United Kingdom), N. Jackson (Manchester, United Kingdom), C. Pattwell (Manchester, United Kingdom), S. Wolosianka (Manchester, United Kingdom), T. Southworth (Manchester, United Kingdom), D. Singh (Manchester, United Kingdom)
|  |
Rhinovirus Challenge in Asthmatics and Healthy Volunteers to Evaluate the Safety and Appropriate Dose of a GMP Human Rhinovirus 16 Preparation for Challenge Studies in Mild-Moderate Asthmatics taking ICS N. Krug (Hannover, Germany), J. Hohlfeld (Hannover, Germany), A. Aliprantis (Kenilworth, New Jersey, United States of America), L. Carayannopoulos (Kenilworth, New Jersey, United States of America), A. Bautmans (Brussels, Belgium), M. Robberechts (Brussels, Belgium), I. De Lepeleire (Brussels, Belgium), H. Ziehr (Braunschweig, Germany), D. Singh (Manchester, United Kingdom), Z. Diamant (Lund, Sweden), S. Yang (Kenilworth, New Jersey, United States of America), N. Fitch (Maasmechelen, Belgium), B. Thornton (Kenilworth, New Jersey, United States of America), P. Sterk (Amsterdam, Netherlands), R. Lutter And The U-Biopred Study Group (Amsterdam, Netherlands)
|  |
Utility of drug reaction assessments for inhaled therapies in patients with chronic suppurative lung diseases: results from 5 years of drug reaction assessments G. Rinaldi (London, United Kingdom), B. Dennis (London, United Kingdom), G. Houseley (London, United Kingdom), O. Shah (London, United Kingdom), M. Loebinger (London, United Kingdom)
|   |
The acute effect of inhaled salbutamol and ipratropium on aortic stiffness and pressure wave reflection H. Al-Rubaye (London, United Kingdom), K. Chauhan (London, United Kingdom), M. Arzim (London, United Kingdom), V. Osman (London, United Kingdom), E. Baker (London, United Kingdom), F. Henry (London, United Kingdom), R. Sachelle (London, United Kingdom), D. Burrage (London, United Kingdom)
|  |
Inhalations of Tranexamic Acid for hemoptysis: A randomized controlled trial O. Wand (Kfar Saba, Israel), E. Guber (Kfar Saba, Israel), A. Guber (Kfar Saba, Israel), G. Epstein-Shochet (Kfar Saba, Israel), L. Israeli-Shani (Kfar Saba, Israel), D. Shitrit (Kfar Saba, Israel)
|   |
Impact of glucagon-like peptide 1 receptor agonists on lung function of diabetic patients: a 52 weeks clinical trial P. Rogliani (Rome, Italy), L. Calzetta (Rome, Italy), A. Coppola (Rome, Italy), M. Cazzola (Rome, Italy), D. Lauro (Rome, Italy), M. Matera (Naples, Italy)
|  |
Novel treatment of eosinophilic bronchitis with allergic fungal sinusitis using mepolizumab- One year follow-up. Y. Takeshita (atami, Japan), S. Nobuyama (atami, Japan), Y. Kanetsuna (atami, Japan), T. Satou (atami, Japan)
|  |
Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations L. Calzetta (Rome, Italy), P. Rogliani (Rome, Italy), E. Puxeddu (Rome, Italy), F. Facciolo (Rome, Italy), M. Cazzola (Rome, Italy), M. Matera (Naples, Italy)
|  |
Characterisation of a chronic pre-clinical model of allergic asthma P. Flajolet (London, United Kingdom), J. De Alba (London, United Kingdom), K. Raemdonck (London, United Kingdom), M. Belvisi (London, United Kingdom), M. Birrell (London, United Kingdom)
|  |